FindTrial
Sign In

Ipilimumab Injection

DRUG6 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University Hospital, Strasbourg, France, NYU Langone Health, Federation Francophone de Cancerologie Digestive, Wu Wenming

Conditions

HCC - Hepatocellular CarcinomaImmunotherapyMelanomaMelanoma (Skin)MesotheliomaMetastatic CancerMetastatic TumorMolecular Targeted Therapy

Phase 1

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis
CompletedNCT03949153
University Hospital, Strasbourg, FranceMelanoma (Skin)
Start: 2019-08-16End: 2022-03-18Updated: 2026-06-05

Phase 2

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Active, not recruitingNCT03918252
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsMesothelioma
Start: 2019-10-02End: 2028-06-01Updated: 2026-06-05
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
RecruitingNCT05428007
NYU Langone HealthMelanoma, Unresectable Melanoma
Start: 2023-02-02End: 2028-02-29Target: 105Updated: 2026-01-05
Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
CompletedNCT05665348
Federation Francophone de Cancerologie DigestiveHCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
Start: 2023-03-09End: 2025-05-12Updated: 2026-03-09
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
Not yet recruitingNCT07715565
West China HospitalImmunotherapy, Molecular Targeted Therapy, Renal Cell Carcinoma (Kidney Cancer)
Start: 2026-08-01End: 2029-12-01Target: 66Updated: 2026-07-20

Unknown Phase

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
RecruitingNCT06353646
Wu WenmingPancreatic Cancer
Start: 2024-03-12End: 2026-12-01Target: 28Updated: 2026-02-13

Related Papers

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.
2026-06-22
Abstract 6453: Serum pharmacodynamic biomarkers of IPI/NIVO/RELA plus sarilumab in Stage III-IV melanoma: Stage 1 results of a Simon Phase II trial (NCT05428007)
Cancer Research2026-04-03
Abstract 4724: Elevated plasma trimethylamine-N-oxide (TMAO) levels correlate with better clinical and molecular responses in immunotherapy-treated resectable gastroesophageal cancer and pleural mesothelioma
Cancer Research2026-04-03
Abstract 1129: Analytical and clinical sensitivity of tumor-informed and tumor-naïve ctDNA residual disease detection during neoadjuvant immune checkpoint inhibition in resectable cancers
Cancer Research2026-04-03
Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses
Nature Medicine2025-09-085 citations
A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma.
Journal of Clinical Oncology2025-05-285 citations
Preliminary safety data of the PRODIGE 81-FFCD 2101-TRIPLET-HCC trial assessing the triple combination atezolizumab-bevacizumab-ipilimumab in patients (pts) treated in systemic therapy for hepatocellular carcinoma (HCC).
Journal of Clinical Oncology2024-06-011 citations
Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial.
2023-02-1618 citations
Trial in progress: Neoadjuvant immune checkpoint blockade in resectable malignant pleural mesothelioma.
Journal of Clinical Oncology2020-05-201 citations